aTyr PharmaATYR -3.61%14 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates ATYR with a GF Score™ of 14/100 and a GF Value™ of $0.46 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 707 Biotechnology companies, aTyr Pharma ranks worse than 141442.57% on this metric.
The historical rank and industry rank for aTyr Pharma's Days Payable or its related term are showing as below:
ATYR's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.76 * Ranked among companies with meaningful Days Payable only.
aTyr Pharma's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
aTyr Pharma Days Payable Related Terms
aTyr Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for aTyr Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, aTyr Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
aTyr Pharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, aTyr Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where aTyr Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
aTyr Pharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
aTyr Pharma (ATYR) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on aTyr Pharma and its competitors. According to the industry distribution chart, aTyr Pharma ranks #999999 out of 707 companies in the Biotechnology industry.
Is aTyr Pharma's Days Payable too high?
aTyr Pharma's current Days Payable is 0.00. Based on the distribution chart, aTyr Pharma ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, aTyr Pharma has a GF Score™ of 14/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's Days Payable compare to HYPD and GOSS?
According to the Biotechnology industry distribution chart, aTyr Pharma ranks #999999 out of 707 companies for Days Payable. This places aTyr Pharma in the lower half of its industry. The industry median Days Payable is 113.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on aTyr Pharma and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. aTyr Pharma's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (ATYR) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.46, compared to a current price of $0.54 — trading 17.3% above its estimated fair value. The current Days Payable is 0.00. aTyr Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For aTyr Pharma (ATYR), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is aTyr Pharma (ATYR) Overvalued in 2026?
Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued.
The current stock price of $0.54 is trading 17.3% above its estimated GF Value™ of $0.46.
GuruFocus considers aTyr Pharma to be Modestly Overvalued.
Key valuation signals for ATYR:
Days Payable: 0.00
GF Value™: $0.46 vs. price of $0.54 (17.3% above fair value)
No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
14GF Score
Get the complete analysis for ATYR
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATYR has been successfully added to your 
